Immunotherapy is a promising strategy to treat refractory diseases.
TriApex has established the Cell Biology & Immunology Evaluation Department, covering the exploration of immune response mechanisms from drug discovery, preclinical research to all phases of clinical trials. We are committed to providing one-stop scientific services for products including immune cell therapies, immunomodulatory drugs, and vaccines, and also use existing platforms and technologies to enable the development of immune system-related drugs.
Target Occupancy (Receptor Occupancy)
ELISPOT (Cytokines and Immunoglobulins)
In vitro Cytokine Release Assay
Cytotoxicity (ADCC/CDC/ADCP, NK activity, T cell cytotoxicity)
Non-immune Cell Phenotyping
Tumors (Solid tumor, hematologic malignancy)
Infection and Secondary Infection
Vaccine (mRNA, recombinant protein)
Adoptive Cell Therapy
Stem Cell therapy
The Cell Biology & Immunology Evaluation Department of TriApex can provide public preventive vaccine research, tumor preventive and therapeutic vaccine research, and CD cell immunity research for various specialized diseases such as oncology, rheumatology, infection, and preventive health care.